Approval · Notice of Compliance 28823 · 2022
TRULICITY: Notice of Compliance 28823
Issued August 25, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28823
- Date
- August 25, 2022
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strengths
Products in this notice
Medicinal ingredients
- DULAGLUTIDE 0.75 MG per 0.5ML
- DULAGLUTIDE 1.5 MG per 0.5ML
- DULAGLUTIDE 3 MG per 0.5ML
- DULAGLUTIDE 4.5 MG per 0.5ML